Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Blood Glucose Monitoring Test Strips Improved

By LabMedica International staff writers
Posted on 24 Nov 2009
A new and improved blood glucose monitoring test strip has been launched.

The Assure Pro blood glucose monitoring system is designed for long-term care and multiresident use settings. More...
Feature loaded, the Assure Pro meter helps facilities meet state regulatory standards and provide better resident care. The strips require 50% less blood, reducing the sample size from 1 µL to only 0.5 µL. All Assure blood glucose-monitoring systems utilize glucose oxidase (GO) strip chemistry, which is not affected by interferences that cause testing errors in other common test strips.

Assure Blood Glucose Meters are backed by the Assure Brilliance program--a comprehensive service program for diabetes management in long-term care (LTC). Assure Brilliance provides customer service, on-site training, Quality Assurance/Quality Control (QA/QC) guidance, diabetes F-Tag advice for LTC, a quarterly newsletter, online CE programs, and more to help facilities manage complex diabetes care in their facilities.

Arkray Inc. (Edina, MN, USA), a manufacturer of diabetes self-monitoring systems, launched the new and improved Blood Glucose Monitoring Test Strip. The company manufactures and distributes cost-effective products that are simple, convenient, and easy-to-use, including blood glucose meters, test strips, safety lancets, and urine chemistry.

Related Links:

Arkray Inc.




Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Rapid Sepsis Test
SeptiCyte RAPID
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Using deep sequencing of cell-free fetal DNA from maternal blood and advanced computational analysis, the method reconstructs fetal variants across the exome (Image credit: Adobe Stock)

Noninvasive Sequencing Test Approaches Invasive Genome Sequencing for Prenatal Screening

Prenatal genetic evaluation guides obstetric care, but standard diagnostics often require invasive procedures that carry risks, stress, and access barriers. Noninvasive prenatal testing (NIPT) has expanded... Read more

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Pathology

view channel
Image: Overview of the uncertainty-aware lensfree computational pathology platform for automated HER2 assessment. A compact lensfree holographic imaging system captures diffraction patterns from immunohistochemically stained breast tissue samples, which are computationally reconstructed and analyzed using deep neural networks with Bayesian uncertainty quantification. (Photo courtesy of Ozcan Lab, UCLA)

Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer

Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.